Expression and purification of human recombinant GST-FGF receptor-1

被引:4
作者
Homann, S [1 ]
Schacher, B [1 ]
Zumstein-Mecker, S [1 ]
Fabbro, D [1 ]
Bold, G [1 ]
Ferrari, S [1 ]
机构
[1] Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland
关键词
FGFR-1; baculovirus; expression; purification;
D O I
10.1016/S0168-1656(00)00399-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
When tumors undergo the angiogenic switch, cell growth and tissue invasion is facilitated by the formation of new capillaries from preexisting blood vessels, a process known as angiogenesis. Growth factors such as vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) and fibroblast growth factor (FGF) trigger the process of angiogenesis. Were we describe a protocol for the expression and one-step purification of human recombinant GST-FGF receptor type 1 (FGFR-1) from Sf9 cells. This protocol allows generating an active kinase as indicated by its reactivity with a monoclonal antibody to phosphorylated tyrosine. The purified enzyme displays a specific activity of 1.2 x 10(4) pmol mg(-1) min(-1), which is in the range of activities reported for homogeneously purified recombinant kinases. We have employed a number of compounds to show that the GST-FGFR-1 preparation is suitable to the identification of tyrosine kinase inhibitors. Considering that inhibitors of angiogenesis may represent an attractive tool in therapeutic strategies targeting invasive metastatic tumors the results presented here, along with available data on the structure of the ATP-binding pocket of FGFR-1, should facilitate the rational design of specific FGFR-1 inhibitory compounds. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 23 条
[1]   Vascular development: Cellular and molecular regulation [J].
Beck, L ;
DAmore, PA .
FASEB JOURNAL, 1997, 11 (05) :365-373
[2]   INHIBITORY ACTIVITY AND SELECTIVITY OF STAUROSPORINE DERIVATIVES TOWARDS PROTEIN-KINASE-C [J].
CARAVATTI, G ;
MEYER, T ;
FREDENHAGEN, A ;
TRINKS, U ;
METT, H ;
FABBRO, D .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (03) :399-404
[3]  
Cruz PE, 1999, BIOTECHNOL BIOENG, V65, P133, DOI 10.1002/(SICI)1097-0290(19991020)65:2<133::AID-BIT2>3.0.CO
[4]  
2-X
[5]   Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent [J].
Fabbro, D ;
Buchdunger, E ;
Wood, J ;
Mestan, J ;
Hofmann, F ;
Ferrari, S ;
Mett, H ;
O'Reilly, T ;
Meyer, T .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :293-301
[6]   Homogeneous purification of human recombinant GST-Akt/PKB from Sf9 cells [J].
Fabbro, D ;
Batt, D ;
Rose, P ;
Schacher, B ;
Roberts, TM ;
Ferrari, S .
PROTEIN EXPRESSION AND PURIFICATION, 1999, 17 (01) :83-88
[7]   ANGIOGENESIS INHIBITORS GENERATED BY TUMORS [J].
FOLKMAN, J .
MOLECULAR MEDICINE, 1995, 1 (02) :120-122
[8]   Blood vessel formation: What is its molecular basis? [J].
Folkman, J ;
DAmore, PA .
CELL, 1996, 87 (07) :1153-1155
[9]   Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta and eta by tumor-promoting and nontumor-promoting agents [J].
Geiges, D ;
Meyer, T ;
Marte, B ;
Vanek, M ;
Weissgerber, G ;
Stabel, S ;
Pfeilschifter, J ;
Fabbro, D ;
Huwiler, A .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (06) :865-875
[10]   Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364